Immunosuppressive effects of rat mesenchymal stem cells: Involvement of CD4+CD25+ regulatory T cells

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 6, 2008, Pages 608-614

  Ye, Zhou ^a,b,c   Wang, Yan ^a,b,c   Xie, Hai Yang ^a,b,c   Zheng, Shu Sen ^a,b,c  

^a BEIJING HOSPITAL   (China)

^b KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Immunosuppression; Mesenchymal stem cells; Regulatory T cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALLOANTIGEN; CYTOKINE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD4+ CD25+ T LYMPHOCYTE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; MITOGENESIS; MIXED CELL CULTURE; NONHUMAN; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD4; CELL DIVISION; CELLS, CULTURED; COCULTURE TECHNIQUES; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MESENCHYMAL STEM CELLS; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57849108938     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49.
3. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213.
4. Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004;229:623-631.
5. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S, et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005;309:314-317.
6. Hong SH, Gang EJ, Jeong JA, Ahn C, Hwang SH, Yang IH, et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun 2005;330:1153-1161.
7. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004;22:377-384.
8. Jeong JA, Gang EJ, Hong SH, Hwang SH, Kim SW, Yang IH, et al. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. Neuroreport 2004;15: 1731-1734.
9. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G, et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood 2005;106:59-66.
10. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729.
11. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48.
12. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33:597-604.
13. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005;33:928-934.
14. Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint SurgAm 2003;85-A:1927-1935.
15. Mahmud N, Pang W, Cobbs C, Alur P, Borneman J, Dodds R, et al. Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model. Exp Hematol 2004;32:494-501.
16. Grinnemo KH, Mansson A, Dellgren G, Klingberg D, Wardell E, Drvota V, et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004; 127:1293-1300.
17. De Kok IJ, Peter SJ, Archambault M, van den Bos C, Kadiyala S, Aukhil I, et al. Investigation of allogeneic mesenchymal stem cell-based alveolar bone formation: preliminary findings. Clin Oral Implants Res 2003;14: 481-489.
18. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
19. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389-397.
20. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307-315.
21. Jiang S, Golshayan D, Tsang J, Lombardi G, Lechler RI. In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Int Immunopharmacol 2006;6:1879-1882.
22. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
23. Tao R, Hancock WW. Regulating regulatory T cells to achieve transplant tolerance. Hepatobiliary Pancreat Dis Int 2007;6:348-357.
24. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
25. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
26. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
27. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195:1641-1646.
28. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, et al. IL-ID is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001;166: 3789-3796.
29. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004; 16:550-557.
30. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
31. Waldmann H, Cobbold S. Exploiting tolerance processes in transplantation. Science 2004;305:209-212.